Message from John Leonard, MD Program Director
“It is my pleasure as director of the WCMC Lymphoma Program to introduce the inaugural issue of our newsletter. We designed this letter to be informative to both patients and clinicians.”
Click here for the full article.
Lymphoma Program Highlights
We believe that the future of oncology lies in targeted, non-chemotherapy drugs. Over the past year, research at WCMC contributed to the FDA approval of ibrutinib, four papers in the New England Journal of Medicine, and multiple presentations at the annual meetings of the American Society of Hematology and the International Conference on Malignant Lymphoma. The following are short summaries of some of our success stories.
Oral Therapy Improves Survival in Chronic Lymphocytic Leukemia
Dr. Richard Furman
Chemotherapy-Free Combination is Active as First-Line Treatment of Mantle Cell Lymphoma
Dr. Jia Ruan
Idelalisib is active in patients with Chemotherapy and Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
Dr. Peter Martin
Clinical Trial Spotlight
This is a select list of our open trials. Currently there are over 30 open trials for various lymphomas at WCMC. A complete listing of our offerings can be found at: http://cornellmedicine.com/trials/
- A051103: A Phase I Study of Rituximab, Lenalidomide, and Ibrutinib in Previously Untreated Follicular Lymphoma: this study seeks to evaluate the side effects and best dose of lenalidomide and ibrutinib for combination with rituximab in previously untreated follicular lymphoma.
- Phase II Study of Lenalidomide + Rituximab for Untreated Mantle Cell Lymphoma: this research study seeks to evaluate the synergy of combining lenalidomide and rituximab to improve treatment effectiveness and maintain quality of life for patients with mantle cell lymphoma.
- Phase III Study of Ibrutinib + R-CHOP for Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma: this study seeks to evaluate whether ibrutinib administered in combination with R-CHOP improves the clinical outcome in newly diagnosed patients with the non-germinal center B-cell subtype of diffuse large B-cell lymphoma.
Patient Experience
A current WCMC patient writes about his experience in seeking treatment with the Lymphoma Program at WCMC.
“In January 2012, I began experiencing a sore right knee, and swollen glands in my neck and left side. Lacking a fever, I went to see my local physician, who agreed I had a palpable mass in my neck, and I was referred to an otolaryngologist for a biopsy. This procedure revealed a preliminary diagnosis of non-Hodgkin lymphoma…” Click here for the full article.
New Developments in Lymphoma 